Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that it has received approval from the Center for Drug Evaluation (CDE) to proceed with the global, placebo-controlled Phase IIb PALIZADE study. The study aims to assess the efficacy and safety of zetomipzomib in patients with active lupus nephritis (LN). Kezar Life Sciences, a partner in the endeavor, will also participate in the study.
Zetomipzomib is a first-in-class selective immunoproteasome inhibitor that is under development for the treatment of various autoimmune diseases, including LN and systemic lupus erythematosus (SLE). In September of this year, Everest Medicines entered into a cooperation and licensing agreement with Kezar Life Sciences. This agreement granted Everest Medicines development and commercialization rights to zetomipzomib in Greater China, South Korea, and certain Southeast Asian countries for a consideration exceeding USD 130 million. Prior clinical trials have demonstrated that zetomipzomab exhibits good safety and tolerability in the treatment of severe and chronic autoimmune diseases.- Flcube.com
